AKAs were suspended in PBS at 200 mg PPA (Millipore Sigma) + 200 mg IPA (Santa Cruz) + 200 mg HPPA (Millipore Sigma) per kg body weight and provided to the mice by gavage. Focal demyelinated mice were treated with AKAs daily from 7 dpl to 14 dpl. The control group received the same volume (100 μL) of PBS via gavage. To prevent coprophagy, mice in AKA treatment and control groups were housed in separate cages from the beginning of treatments.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.